The frequency of metaphases without a Philadelphia chromosome was determined in mitogen-stimulated cultures of peripheral blood mononuclear cells (PBMC) and purified T lymphocytes (93% CD2-positive) from a patient with chronic myelogenous leukemia (CML) for 28 years. The PBMC cultures contained few Ph-negative cells (8%), but they constituted 92% of the metaphases in T cell cultures, indicating few if any Ph-positive T cells in the patient's circulation. The results demonstrate that T cells derived from the leukemic clone may fail to replace the non-neoplastic population even when CML arises in childhood and the patient survives for many years. This raises questions concerning the normal role of the bone marrow as a source of T cells after infancy, and also whether Ph-positive lymphocytes may be at a disadvantage for growth.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0145-2126(89)90009-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab.
Blood Cancer J
November 2024
Division of Hematology, EA3518 Saint-Louis Institute for Research, Saint-Louis Hospital, Paris, France.
This narrative review seeks to summarize chemotherapeutic regimens commonly used for patients with newly diagnosed Philadelphia (Ph) chromosome-negative B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in the frontline setting and to describe the latest clinical research using the bispecific T-cell-engaging immunotherapy blinatumomab in the first-line treatment setting. Current standard-of-care chemotherapeutic backbones for newly diagnosed Ph-negative BCP-ALL are based on the same overarching treatment principle: to reduce disease burden to undetectable levels and maintain lasting remission. The adult treatment landscape has progressively evolved following the adoption of pediatric-inspired regimens.
View Article and Find Full Text PDFAcute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
October 2024
National Comprehensive Cancer Network.
Article Synopsis
- - The NCCN Guidelines for acute lymphoblastic leukemia (ALL) offer management recommendations that prioritize classifying ALL subtypes using immunophenotype and cytogenetic/molecular markers.
- - The guidelines emphasize risk assessment and stratification to tailor therapy for both Ph-positive and Ph-negative ALL, specifically addressing treatment for adolescent, young adult, and adult patients.
- - This excerpt highlights treatment recommendations specifically for adults newly diagnosed with Ph-negative ALL, grounded in the latest evidence-based research.
Biallelic Loss of 7q34 () and 9p21.3 (/) in Adult Ph-Negative Acute T-Lymphoblastic Leukemia.
Int J Mol Sci
September 2024
National Medical Research Center for Hematology, 125167 Moscow, Russia.
Tumor cells of acute lymphoblastic leukemia (ALL) may have various genetic abnormalities. Some of them lead to a complete loss of certain genes. Our aim was to reveal biallelic deletions of genes in Ph-negative T-ALL.
View Article and Find Full Text PDFPh-negative Myeloproliferative Neoplasm is a rare yet dangerous disease that can turn into more severe forms of disorders later on. Clinical diagnosis of the disease exists but often requires collecting multiple types of pathologies which can be tedious and time-consuming. Meanwhile, studies on deep learning-based research are rare and often need to rely on a small amount of pathological data due to the rarity of the disease.
View Article and Find Full Text PDFPhiladelphia-like B-cell acute lymphoblastic leukaemia: Disease features and outcomes in the era of immunotherapy.
Br J Haematol
December 2024
Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Norris Comprehensive Cancer Center, Los Angeles, California, USA.
Philadelphia chromosome (Ph)-like acute lymphoblastic leukaemia (ALL) is a high-risk subtype with a gene expression profile similar to Ph-positive ALL, due to activation of tyrosine kinase signalling. To understand the clinical implications of Ph-like ALL, this single-centre retrospective study evaluates outcomes in 268 adults, largely Hispanic ALL patients treated between 2013 and 2024, with a subgroup analysis of 139 haematopoietic stem cell transplantation (HSCT) patients. ALL subtypes included 68 (25.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!